U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230119) titled 'A Phase 3 Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)' on Nov. 13.
Brief Summary: This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving >= 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
Study Start Date: March 08, 2026
Study Type: INTERVENTIONAL
Condition:
Overweight , Obesity
Intervention:
DRUG: Zovaglutide dose 1
administered subcutaneously (SC), Q4W
DRUG: Zovaglutide dose 2
administered subcutaneously (SC), Q4W
DRUG: Placebo
administered subcutaneously (SC), Q4W
Recruit...